ProfileGDS4814 / ILMN_2089458
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 79% 80% 81% 79% 81% 81% 80% 79% 77% 80% 79% 76% 80% 80% 80% 79% 80% 79% 79% 80% 81% 79% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)128.89579
GSM780708Untreated after 4 days (C2_1)141.17280
GSM780709Untreated after 4 days (C3_1)151.27881
GSM780719Untreated after 4 days (C1_2)136.66779
GSM780720Untreated after 4 days (C2_2)155.14381
GSM780721Untreated after 4 days (C3_2)155.39281
GSM780710Trastuzumab treated after 4 days (T1_1)143.05880
GSM780711Trastuzumab treated after 4 days (T2_1)134.80279
GSM780712Trastuzumab treated after 4 days (T3_1)117.92377
GSM780722Trastuzumab treated after 4 days (T1_2)144.77780
GSM780723Trastuzumab treated after 4 days (T2_2)134.07179
GSM780724Trastuzumab treated after 4 days (T3_2)106.14976
GSM780713Pertuzumab treated after 4 days (P1_1)146.01380
GSM780714Pertuzumab treated after 4 days (P2_1)145.72180
GSM780715Pertuzumab treated after 4 days (P3_1)143.02980
GSM780725Pertuzumab treated after 4 days (P1_2)133.379
GSM780726Pertuzumab treated after 4 days (P2_2)142.53380
GSM780727Pertuzumab treated after 4 days (P3_2)137.35679
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)129.27379
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)142.88980
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)155.88881
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)128.10379
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)149.53880